MYC plus class IIa HDAC inhibition drives mitochondrial dysfunction in non-small cell lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Targeting the MYC oncoprotein is crucial, but combination strategies are needed for effective cancer treatment.
• Class IIa histone deacetylases (HDAC5 and HDAC9) are implicated in cancer progression and represent potential therapeutic targets.
• Non-small cell lung cancer (NSCLC) often exhibits high MYC expression and mitochondrial activity, suggesting vulnerability to combined therapies.

Purpose of the Study:

• To identify novel therapeutic targets in combination with MYC inhibition for cancer treatment.
• To investigate the efficacy of dual targeting of MYC and class IIa HDACs in NSCLC.
• To elucidate the molecular mechanisms underlying the combination therapy's anti-tumor effects.

Main Methods:

• Transcriptome data analysis of cancer cell lines treated with MYC inhibitors.
• In vitro viability assays and molecular analyses (ROS, MYC levels) in NSCLC cell lines.
• In vivo efficacy studies in animal models with correlative molecular analyses.

Main Results:

• Identification of HDAC5 and HDAC9 as potential therapeutic targets in conjunction with MYC inhibition.
• Dual targeting of MYC and class IIa HDACs significantly reduced NSCLC cell viability.
• Combination treatment led to MYC suppression, elevated mitochondrial ROS, and demonstrated in vivo anti-tumor efficacy.

Conclusions:

• A combination therapy targeting MYC and class IIa HDACs is a promising strategy for NSCLC treatment.
• The efficacy of this combination is linked to MYC depletion and mitochondrial dysfunction.
• This approach offers a novel therapeutic avenue for exploiting MYC vulnerability in NSCLC.